Derm News: 2006(22)

Cost Effectiveness of Management of Mild-to-Moderate Atopic Dermatitis with 1% Pimecrolimus Cream in Children and Adolescents 2-17 Years of Age

American Journal of Clinical Dermatology
Charles N Ellis; Kristijan H Kahler; Jens Grueger; Jane Chang

Introduction

Atopic dermatitis (AD) has the potential to cause a long-term economic impact on patients, their families, and the healthcare system.

Objective

To determine if 1% pimecrolimus cream is cost-effective in treating mild-to-moderate AD in patients 2-17 years of age.

Methods

Data on the efficacy of AD management with 1% pimecrolimus cream (Elidel(R), Novartis Pharma GmbH, Wehr, Germany) were obtained from a 12-month, randomized, double-blind, multinational, controlled clinical trial comparing pimecrolimus and conventional therapy. Markov modeling was used for the economic model, based on: (i) Investigator's Global Assessment scores assessed at each visit during the clinical trial; (ii) estimated costs for medication and physician visits for each level of disease severity; and (iii) utility values for each level of disease severity. The perspective was that of a third-party payer.

Results

In 2004 US dollars, the incremental cost-effectiveness of 1% pimecrolimus cream was $US38 231 per quality-adjusted life year (QALY) gained compared with conventional therapy. Sensitivity analyses showed a range of $US27 299 to $US63 457 per QALY gained.

Conclusion

With an incremental cost-effectiveness ratio of <$US50 000 per QALY gained, 1% pimecrolimus cream offers a cost-effective therapeutic option in the management of AD.

    Back to Current Volume:   Dermatology News 2006

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.